Kazia Therapeutics Limited Stock Prediction and Forecast [KZIA]

AI-generated source summary

The analysis focuses on Kazia Therapeutics (KZIA). Our system classified KZIA as hold/accumulate, assigning it a score of -0.350. KZIA is positioned at the upper end of a declining short-term trend. A breakout above $7.42 may slow the decline. There is possible 17.82% decline over three months, with returns between 33.78% down to 16.47%. The 12-month analysis expects about 64.75% decline. The price increased 4.58% on the last trading day, fluctuating by 12.90% between $6.51 and $7.35, making it a medium-risk stock. SVB Leerink rated KZIA as Market Perform, while H.C. Wainwright gave a Buy rating and there's a buy signal from 3-month Moving Average Convergence Divergence (MACD), but a sell signal given from a long term moving average. Key trading levels include resistance at $8.00 and support at $7.14. A suggested stop-loss is set at $6.94, a 5% decline.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   28 Oct 2025, 03:02 UTC

   The analyst published the original source item.

2. First prediction resolved

   31 Oct 2025, 15:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   31 Oct 2025, 15:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:12 UTC

   Tahlil Plus began monitoring the extracted predictions.